CY1106733T1 - Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη - Google Patents

Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη

Info

Publication number
CY1106733T1
CY1106733T1 CY20071100943T CY071100943T CY1106733T1 CY 1106733 T1 CY1106733 T1 CY 1106733T1 CY 20071100943 T CY20071100943 T CY 20071100943T CY 071100943 T CY071100943 T CY 071100943T CY 1106733 T1 CY1106733 T1 CY 1106733T1
Authority
CY
Cyprus
Prior art keywords
erythropoietin
treatment
fructopyranoses
neurological dysfunction
dysfunction including
Prior art date
Application number
CY20071100943T
Other languages
English (en)
Inventor
Carlos R. Plata-Salaman
Virginia L. Smith-Swintosky
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of CY1106733T1 publication Critical patent/CY1106733T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Συν-θεραπεία για την αγωγή νευρολογικών περιλαμβάνουσα τη χορήγηση μίας ή περισσότερων σουλφαμικών φρουκτοπυρανοζών και ερυθροποιητίνης.
CY20071100943T 2001-02-02 2007-07-13 Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη CY1106733T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (1)

Publication Number Publication Date
CY1106733T1 true CY1106733T1 (el) 2012-05-23

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100943T CY1106733T1 (el) 2001-02-02 2007-07-13 Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη

Country Status (17)

Country Link
US (2) US6908902B2 (el)
EP (1) EP1471871B1 (el)
JP (1) JP2005501801A (el)
KR (1) KR100896971B1 (el)
AT (1) ATE361089T1 (el)
CA (1) CA2437333A1 (el)
CY (1) CY1106733T1 (el)
DE (1) DE60219961T8 (el)
DK (1) DK1471871T3 (el)
ES (1) ES2284858T3 (el)
MX (1) MXPA03006952A (el)
NO (1) NO20033440L (el)
NZ (1) NZ548578A (el)
PT (1) PT1471871E (el)
RU (1) RU2317086C2 (el)
WO (1) WO2002064085A2 (el)
ZA (1) ZA200306818B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
PT1471871E (pt) * 2001-02-02 2007-06-05 Ortho Mcneil Pharm Inc Tratamento de disfunção neurológica compreendendo sulfamatos de frutopiranose e eritropoietina
EP1423127A1 (en) * 2001-08-30 2004-06-02 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
CN100502856C (zh) * 2002-09-17 2009-06-24 默塔克神经科学有限公司 运动障碍的治疗
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2007020922A1 (ja) * 2005-08-17 2007-02-22 Chugai Seiyaku Kabushiki Kaisha 脳疾患の治療剤および予防剤
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8603980B2 (en) 2007-01-16 2013-12-10 The Johns Hopkins University Glutamate receptor antagonists and methods of use
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
CA2724841A1 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP4273164A3 (en) 2009-10-09 2024-01-24 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
CN104220064B (zh) 2012-03-23 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1995003034A1 (en) 1993-07-19 1995-02-02 Amgen Inc. Stabilization of aerosolized proteins
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
KR20000029673A (ko) 1996-08-02 2000-05-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
TR200000175T2 (tr) 1997-07-23 2001-01-22 Roche Diagnostics Gmbh Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
DK0902085T3 (da) 1997-09-01 2004-04-05 Aventis Pharma Gmbh Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
CA2330527A1 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
AU782344C (en) 1999-04-08 2006-08-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
NZ545478A (en) * 1999-04-13 2008-04-30 Kenneth S Warren Inst Inc Modulation of excitable tissue function by peripherally administered erythropoietin
PT1471871E (pt) * 2001-02-02 2007-06-05 Ortho Mcneil Pharm Inc Tratamento de disfunção neurológica compreendendo sulfamatos de frutopiranose e eritropoietina

Also Published As

Publication number Publication date
DE60219961T2 (de) 2008-01-17
EP1471871A2 (en) 2004-11-03
WO2002064085A2 (en) 2002-08-22
ZA200306818B (en) 2005-02-23
NO20033440L (no) 2003-09-29
JP2005501801A (ja) 2005-01-20
RU2317086C2 (ru) 2008-02-20
EP1471871B1 (en) 2007-05-02
PT1471871E (pt) 2007-06-05
KR100896971B1 (ko) 2009-05-14
NZ548578A (en) 2008-03-28
DE60219961D1 (de) 2007-06-14
WO2002064085A3 (en) 2004-09-10
ATE361089T1 (de) 2007-05-15
RU2003124059A (ru) 2005-01-27
MXPA03006952A (es) 2004-10-15
US6908902B2 (en) 2005-06-21
ES2284858T3 (es) 2007-11-16
DE60219961T8 (de) 2008-04-17
US20020169109A1 (en) 2002-11-14
US20050261182A1 (en) 2005-11-24
EP1471871A4 (en) 2005-11-09
CA2437333A1 (en) 2002-08-22
NO20033440D0 (no) 2003-08-01
KR20040011458A (ko) 2004-02-05
DK1471871T3 (da) 2007-09-17

Similar Documents

Publication Publication Date Title
CY1106733T1 (el) Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη
EE05417B1 (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
AR037109A1 (es) Uso de flibanserina
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
CY1110570T1 (el) Χρηση της ουριδινης σε συνδυασμο με χολινη για τη θεραπεια διαταραχων της μνημης
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DK1419154T3 (da) Rapamycin-29-enoler
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
PT1073658E (pt) Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
BR0110028A (pt) Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
ITBO20000453A0 (it) Apparecchiatura e procedimento per la sterilizzazione del terreno .
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DK1220852T3 (da) Substituerede diazepaner
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
AR023199A1 (es) Solucion acuosa estable de em12, y procedimiento de preparacion de dicha solucion
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
NO20005548D0 (no) Mykobakterieinhibitorer
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
BR0206918A (pt) Uso de iloperidona